These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 1850941

  • 21. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
    Dzau VJ.
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):74-80. PubMed ID: 3037893
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Hemodynamic results of perorally administered converting enzyme inhibitors in congestive heart failure.
    Lantz P, Enghoff E, Hedlund A, Hägg A.
    Scand J Urol Nephrol Suppl; 1984 Jul; 79():129-32. PubMed ID: 6089312
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril.
    Morisco C, Condorelli M, Crepaldi G, Rizzon P, Zardini P, Villa G, Argenziano L, Trimarco B.
    Cardiovasc Drugs Ther; 1997 Mar; 11(1):63-9. PubMed ID: 9140680
    [Abstract] [Full Text] [Related]

  • 26. [Comparison of enalapril and captopril in the treatment of chronic heart failure].
    Tjon-A-Meeuw L, Hess OM, Greminger P, Maire R, Jenni R, Krayenbuehl HP.
    Z Kardiol; 1990 Jun; 79(6):429-35. PubMed ID: 2198731
    [Abstract] [Full Text] [Related]

  • 27. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS).
    Chockalingam A, Venkatesan S, Subramaniam T, Jagannathan V, Elangovan S, Alagesan R, Gnanavelu G, Dorairajan S, Krishna BP, Chockalingam V, Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis.
    Am Heart J; 2004 Apr; 147(4):E19. PubMed ID: 15077102
    [Abstract] [Full Text] [Related]

  • 28. [Effect of long-term treatment with enalapril, losartan and their combination on the quality of life of patients with congestive heart failure].
    Vizir VA, Berezin AE.
    Ter Arkh; 2002 Apr; 74(1):52-5. PubMed ID: 11878061
    [Abstract] [Full Text] [Related]

  • 29. Clinical experience with lisinopril in congestive heart failure. Focus on the older patient.
    Giles TD.
    Drugs; 1990 Apr; 39 Suppl 2():17-22. PubMed ID: 2160883
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Angiotensin converting enzyme inhibitors. Disparities in the mechanism of their antihypertensive effect.
    Garavaglia GE, Messerli FH, Nunez BD, Schmieder RE, Frohlich ED.
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):214S-216S. PubMed ID: 2843195
    [Abstract] [Full Text] [Related]

  • 32. Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: a multiple-propensity analysis.
    Chitnis AS, Aparasu RR, Chen H, Johnson ML.
    Res Social Adm Pharm; 2012 Jul; 8(2):145-56. PubMed ID: 21511540
    [Abstract] [Full Text] [Related]

  • 33. [Undesirable effects and interaction to angiotensin converting enzyme inhibitors therapy].
    Ionescu SD, Sandru V, Leuciuc E, Manea P, Burdujan A, Tovarniţchi S, Cosovanu A.
    Rev Med Chir Soc Med Nat Iasi; 2002 Jul; 106(1):128-31. PubMed ID: 12635373
    [Abstract] [Full Text] [Related]

  • 34. Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.
    Langtry HD, Markham A.
    Drugs Aging; 1997 Feb; 10(2):131-66. PubMed ID: 9061270
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Left ventricular performance after intravenous infusion of captopril in patients with congestive heart failure.
    Arcidiacono G, Asmundo GO, Battaglia E, Bordignon E, Calogero AE, Cuscunà S, Floridia S, Vigo G, Ossino AM, Gurgone G.
    Minerva Cardioangiol; 1995 Feb; 43(11-12):481-4. PubMed ID: 8710137
    [Abstract] [Full Text] [Related]

  • 37. Duration of angiotensin-converting enzyme inhibition: implications for tolerability.
    Murray NH.
    Cardiology; 1991 Feb; 79 Suppl 1():22-9. PubMed ID: 1655262
    [Abstract] [Full Text] [Related]

  • 38. Lisinopril: a new angiotensin-converting enzyme inhibitor.
    Armayor GM, Lopez LM.
    Drug Intell Clin Pharm; 1988 May; 22(5):365-72. PubMed ID: 2839326
    [Abstract] [Full Text] [Related]

  • 39. Long- versus short-acting angiotensin-converting enzyme inhibitors.
    Ikram H, White HD.
    J Am Coll Cardiol; 1990 Jan; 15(1):250-1. PubMed ID: 2153158
    [No Abstract] [Full Text] [Related]

  • 40. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses.
    Uretsky BF, Shaver JA, Liang CS, Amin D, Shah PK, Levine TB, Walinsky P, LeJemtel T, Linnemeier T, Rush JE.
    Am Heart J; 1988 Aug; 116(2 Pt 1):480-8. PubMed ID: 2840815
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.